Published in Neurol Clin on October 01, 2004
Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria? Genes Brain Behav (2007) 1.07
Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues. J Clin Neurol (2005) 0.75
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med (2008) 6.86
Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol (2004) 6.14
Levodopa and the progression of Parkinson's disease. N Engl J Med (2004) 5.44
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol (2008) 4.16
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
"Psychogenic movement disorders": they are what they are. Mov Disord (2014) 2.56
Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem (2007) 2.40
The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann Neurol (2008) 2.27
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain (2013) 2.09
Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord (2008) 1.98
Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol (2003) 1.91
Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis (2009) 1.90
Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord (2007) 1.85
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA (2004) 1.71
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
The pattern of cognitive-functional decline in elderly essential tremor patients: an exploratory-comparative study with Parkinson's and Alzheimer's disease patients. J Am Med Dir Assoc (2009) 1.59
Brainstem pathology in DYT1 primary torsion dystonia. Ann Neurol (2004) 1.55
Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. Sleep Med (2003) 1.52
Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann Neurol (2008) 1.47
The neuropathology of manganese-induced Parkinsonism. J Neuropathol Exp Neurol (2007) 1.42
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord (2010) 1.39
The pathogenesis of cell death in Parkinson's disease. Neurology (2006) 1.38
Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci (2002) 1.35
Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol (2005) 1.27
Early single cell bifurcation of pro- and antiapoptotic states during oxidative stress. J Biol Chem (2004) 1.24
Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem (2002) 1.22
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol (2002) 1.22
Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord (2007) 1.17
Neuroprotection in Parkinson's disease: clinical trials. Ann Neurol (2003) 1.15
Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport (2002) 1.15
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology (2013) 1.14
Movement disorders and AIDS: a review. Parkinsonism Relat Disord (2004) 1.12
Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett (2002) 1.11
Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann Neurol (2003) 1.10
Overexpression of torsinA in PC12 cells protects against toxicity. J Neurochem (2004) 1.08
Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol Aging (2005) 1.08
Unilateral stimulation of the subthalamic nucleus in Parkinson disease: a double-blind 12-month evaluation study. J Neurosurg (2004) 1.05
p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J Biol Chem (2006) 0.99
Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J (2003) 0.97
Proteasome inhibitor-induced model of Parkinson's disease. Ann Neurol (2006) 0.95
Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses. J Biol Chem (2008) 0.95
Treatment of levodopa-induced motor complications. Mov Disord (2008) 0.95
Clinical usefulness of the Parkinson's disease sleep scale. Parkinsonism Relat Disord (2005) 0.92
Open-label surgical trials for Parkinson disease: time for reconsideration. Ann Neurol (2011) 0.91
Stem cell treatment for Parkinson's disease: an update for 2005. Curr Opin Neurol (2005) 0.90
Sleepiness in Parkinson's disease: a controlled study. Mov Disord (2003) 0.90
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord (2004) 0.89
Proteasomal dysfunction in sporadic Parkinson's disease. Neurology (2006) 0.88
Modeling Parkinson's disease. Ann Neurol (2009) 0.88
Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease. Neurology (2006) 0.88
Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself? Exp Neurol (2007) 0.88
Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann Neurol (2003) 0.87
Neuroprotection for Parkinson's disease: prospects and promises. Ann Neurol (2003) 0.87
Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain (2002) 0.85
Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapy. Mt Sinai J Med (2007) 0.84
Levodopa toxicity and Parkinson disease: still a need for equipoise. Neurology (2011) 0.84
Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord (2011) 0.83
Obstacles to the development of a neuroprotective therapy for Parkinson's disease. Mov Disord (2013) 0.83
Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther (2003) 0.82
Levodopa-induced dyskinesias in the absence of nigrostriatal degeneration. Mov Disord (2013) 0.81
Toxicity of glutathione depletion in mesencephalic cultures: a role for arachidonic acid and its lipoxygenase metabolites. Eur J Neurosci (2004) 0.80
Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology (2004) 0.79
Frequency-velocity mismatch: a fundamental abnormality in parkinsonian gait. J Neurophysiol (2009) 0.78
Stem cells for Parkinson's disease: advancing science but protecting patients. Mov Disord (2012) 0.78
A model-based approach for assessing parkinsonian gait and effects of levodopa and deep brain stimulation. Conf Proc IEEE Eng Med Biol Soc (2006) 0.78
Prevalence of movement disorders in an elderly nursing home population. Arch Gerontol Geriatr (2007) 0.78
Unmet medical needs in Parkinson's disease. Neurology (2004) 0.78
Differential role of dopamine in emotional attention and memory: evidence from Parkinson's disease. Mov Disord (2011) 0.78
Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Mov Disord (2014) 0.78
Double-blind, placebo-controlled trials for surgical interventions in Parkinson disease. Arch Neurol (2005) 0.77
Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin Neuropharmacol (2012) 0.77
Progress in clinical neurosciences: a forum on the early management of Parkinson's disease. Can J Neurol Sci (2005) 0.77
Parkinson's disease: unresolved issues. Ann Neurol (2008) 0.77
Emotional processing affects movement speed. J Neural Transm (Vienna) (2011) 0.77
Reply to: psychogenic movement disorders: what's in a name? Mov Disord (2014) 0.76
A colonic biomarker of Parkinson's disease? Mov Disord (2012) 0.76
Technical advances in deep brain stimulation: how far is enough? Mov Disord (2012) 0.75
Reply to "declining medication requirement in some patients with advanced Parkinson disease and dementia". Clin Neuropharmacol (2004) 0.75
A changing journal for a changing field. Mov Disord (2010) 0.75
Skin picking in Parkinson's disease: a behavioral side-effect of dopaminergic treatment? Psychiatry Clin Neurosci (2010) 0.75
Scientific perspectives. Mov Disord (2014) 0.75
Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets. Mov Disord (2010) 0.75
Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon. J Am Med Dir Assoc (2006) 0.75
Melvin David Yahr, MD (1917-2004). Neurology (2004) 0.75
Preserved emotional modulation of motor response time despite psychomotor slowing in young-old adults. Int J Neurosci (2011) 0.75
Movement disorders 2011--the state of the journal. Mov Disord (2011) 0.75
Physical therapy in Parkinson's disease. Handb Clin Neurol (2007) 0.75